7 January 2015
Juno completes IPO
Juno Therapeutics completes initial public offering, with stocks soaring.
Author: Gregg Bayes-Brown, editor
Immunotherapy firm Juno Therapeutics has completed its IPO, trading on the Nasdaq under the ticker symbol “JUNO” since 22 December.
Juno offered 12.7 million shares of common stock at $24 per share. By 29 December, the share price had more than doubled to $54 per share. After a sell off at the start of the year bringing the price down to $46 per share, the price has subsequently recovered to $51.66 per share at time of writing.
The company, launched in December 2013, raised $310m over two rounds in 12 months. Backers include Bezos Expeditions, Arch Venture Partners, Venrock, and Alaska Permanent Fund.
At the core of Juno’s intellectual property is an oncology treatment which reprograms white blood cells to be able to recognise, target, and eradicate tumours. Early trials into the technology at Juno and its immunotherapy peers have shown a great deal of promise, with a high rate of complete remissions.
Supporting articles: Juno brings big guns against cancer / Juno extends series A to $145m / Juno tops up series A to $176m / Tracking the billions: activity during the first half of 2014 / Juno shoots for $134m series B / Big Deal: Juno Therapeutics / Deal of the Year 2014: Juno Therapeutics / Juno targets cancer with IPO / Juno aims for $213m IPO / Juno completes IPO
Copyright Mawsonia Limited 2010. Please don´t cut articles from www.globaluniversityventuring.com or the PDF and redistribute by email or post to the web without written permission.